143 related articles for article (PubMed ID: 37880845)
1. The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea.
Kim K; Kim DG; Lee JG; Joo DJ; Lee HW
Yonsei Med J; 2023 Nov; 64(11):647-657. PubMed ID: 37880845
[TBL] [Abstract][Full Text] [Related]
2. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
3. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
4. Development of a Korean Liver Allocation System using Model for End Stage Liver Disease Scores: A Nationwide, Multicenter study.
Lee J; Lee JG; Jung I; Joo DJ; Kim SI; Kim MS;
Sci Rep; 2019 May; 9(1):7495. PubMed ID: 31097768
[TBL] [Abstract][Full Text] [Related]
5. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
6. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
Ioannou GN; Perkins JD; Carithers RL
Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
Taniguchi M
Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
[TBL] [Abstract][Full Text] [Related]
9. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
10. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
[TBL] [Abstract][Full Text] [Related]
11. Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.
Hong YF; Chen ZH; Ma XK; Li X; Wu DH; Chen J; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Wen JY; Lin Q; Jia CC; Wu XY
Tumour Biol; 2016 Apr; 37(4):5265-73. PubMed ID: 26561464
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
13. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
14. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
16. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
[TBL] [Abstract][Full Text] [Related]
17. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score.
Wong RJ; Devaki P; Nguyen L; Cheung R; Cho-Phan C; Nguyen MH
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1534-40.e1. PubMed ID: 24361414
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions.
Bittermann T; Goldberg DS; Bauer CM; Khungar V
Transplantation; 2017 May; 101(5):1099-1105. PubMed ID: 28121908
[TBL] [Abstract][Full Text] [Related]
19. The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.
Freitas AC; Itikawa WM; Kurogi AS; Stadnik LG; Parolin MB; Coelho JC
Arq Gastroenterol; 2010; 47(3):233-7. PubMed ID: 21140081
[TBL] [Abstract][Full Text] [Related]
20. Waitlist mortality and post-liver transplant outcomes of pediatric patients with hepatocellular carcinoma and hepatoblastoma in the United States.
Wu WK; Ziogas IA; Matsuoka LK; Izzy M; Pai AK; Benedetti DJ; Alexopoulos SP
Pediatr Blood Cancer; 2022 Jan; 69(1):e29425. PubMed ID: 34736292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
